Please use this identifier to cite or link to this item: http://hdl.handle.net/11434/655
Title: Re: chemohormonal therapy in metastatic hormone-sensitive prostate cancer
Epworth Authors: Murphy, Declan
Other Authors: Zargar, Homayoun
Keywords: CHAARTED Trial
Metastatic Prostate Cancer
Docetaxel Chemotherapy
DC
Androgen Deprivation Therapy
Issue Date: Mar-2016
Publisher: Elsevier
Citation: Eur Urol. 2016 Mar;69(3):540
Abstract: Comment on the landmark study of men with advanced prostate cancer tested the hypothesis that addition of docetaxel chemotherapy (DC) to androgen deprivation therapy (ADT) at the time of treatment initiation would lead to improved overall survival in men with metastatic prostate cancer (CHAARTED trial).
URI: http://hdl.handle.net/11434/655
DOI: 10.1016/j.eururo.2015.12.027.
PubMed URL: http://www.ncbi.nlm.nih.gov/pubmed/26867727
ISSN: 0302-2838
Journal Title: European Urology
Type: Comments
Affiliated Organisations: Division of Cancer Surgery, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Australia
Department of Urology, Royal Melbourne Hospital, Melbourne, Australia.
Appears in Collections:Cancer Services
UroRenal, Vascular
Epworth Prostate Centre

Files in This Item:
There are no files associated with this item.


Items in EKB are protected by copyright, with all rights reserved, unless otherwise indicated.